Sally E. Blount
Director at Abbott Laboratories (ABT)
Sally E. Blount has filed 8 insider reports with the SEC since April 2021, as director at Abbott Laboratories (ABT) and director at Ulta Beauty, Inc. (ULTA). Sally E. Blount made no open-market purchases or sales in the last 12 months. The latest filing, on April 28, 2026, reports grant or award at Abbott Laboratories (ABT).
- Filings
- 8
- Companies
- 2
- Bought on market
- None
- Sold on market
- $337K
Companies where Sally E. Blount is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Director | 36,344 | $337K | $103.00 | Apr 28, 2026 | |||
| Director | $615.74 | Jun 3, 2021 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Apr 24, 2026ABTDirector Blount Sally E. was granted 2,286 units of Common shares without par value, increasing direct ownership by 7% to 36,344 unitsForm 4Grant or award
- Apr 30, 2025-$337KABTDirector Blount Sally E. sold $337,116 worth of Common shares without par value (2,600 units at $129.66), decreasing direct ownership by 7% to 34,058 unitsForm 4Open-market sale
- Apr 25, 2025ABTDirector Blount Sally E. was granted 1,635 units of Common shares without par value, increasing direct ownership by 5% to 36,658 unitsForm 4Grant or award
- Apr 26, 2024ABTBlount Sally E. was granted 1,866 units of Common shares without par value, increasing direct ownership by 6% to 35,023 unitsForm 4Grant or award
- Apr 28, 2023ABTSEC Form 4 filed by Blount Sally E.Form 4Grant or award
- Apr 29, 2022ABTSEC Form 4: Blount Sally E. was granted 1,602 units of Common shares without par value, increasing direct ownership by 5% to 31,341 unitsForm 4Grant or award
- Jun 2, 2021ULTASEC Form 4 filed by Blount Sally E.Form 4Grant or award
- Apr 23, 2021ABTSEC Form 4: Blount Sally E. was granted 1,499 units of Common shares without par value, increasing direct ownership by 5% to 29,739 unitsForm 4Grant or award
Compare Sally E. Blount with
- Sally E. Blount vs Mary K Moreland1 shared
- Sally E. Blount vs John G Stratton1 shared
- Sally E. Blount vs Patricia Paola Gonzalez1 shared
- Sally E. Blount vs Kevin T Conroy1 shared
- Sally E. Blount vs Nita Ahuja1 shared
- Sally E. Blount vs Michael F Roman1 shared
Other insiders at the same companies
- Mary K MorelandABT
- John G StrattonABT
- Patricia Paola GonzalezABT
- Kevin T ConroyABT
- Nita AhujaABT
- Michael F RomanABT
- Kecia SteelmanULTA
- Lorna NaglerULTA
- John A. Mccoy Jr.ABT
- Philip P BoudreauABT
- Brieane Lee OlsonULTA
- Robert B FordABT
- Louis H. MorroneABT
- Elizabeth C. CushmanABT
- George R Mrkonic JrULTA
- Mike C. SmithULTA
Questions about Sally E. Blount
- What is Sally E. Blount's role at Abbott Laboratories?
- Sally E. Blount reports to the SEC as director at Abbott Laboratories (ABT), according to the latest filing on April 28, 2026. Sally E. Blount has also filed as director at Ulta Beauty, Inc. (ULTA).
- How many shares does Sally E. Blount own?
- After the latest filing that states it, Sally E. Blount directly owned 36,344 shares of Abbott Laboratories (ABT). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Sally E. Blount bought or sold stock recently?
- The most recent open-market sale was on April 30, 2025: sold 2,600 shares of Abbott Laboratories (ABT) for $337K at an average of $129.66.
- How do I get alerts when Sally E. Blount files?
- Follow Sally E. Blount on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Sally E. Blount (SEC CIK 0001537286). Totals count each trade once, skipping amendments whose original is on file, from Apr 27, 2021 on. View on SEC EDGAR · Get this as JSON